DUBLIN, Aug. 28, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/jq34zf/investigation) has announced the addition of the "Investigation Report on China's Tobramycin Market, 2010-2019" report to their offering.
Tobramycin is a traditional antibiotic whose eye drop and ointment are the most common prescription drugs for the treatment of potential infection or inflammation caused by eye infection. Currently, dozens of enterprises in China are able to produce tobramycin, among which the Top 5 are s.a. Alcon- Couvreur n.v., Sine Pharma, Kangya of Ningxia Pharmaceuticals Co., Ltd, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd and Shanghai Harvest Pharmaceutical Co., Ltd who together dominate the market by taking up a share of over 90%.
Tobramycin has begun to stabilize in recent years despite a rapid development ever since its entry into China. According to the statistics of 22 sample hospitals in key cities, the sales value of tobramycin was CNY 20.12 million in 2014 with a year-on-year growth of 3.93% and CAGR during the period of 2010- 2014 reached 1.22%. As the incidence of eye disease keeps going up, tobramycin still enjoys a vast market in China. Although s.a. Alcon- Couvreur n.v. took up the largest market share of about 72% for sales value in 2014, local enterprises reported a fast growth in market share due to their increasing emphasis on ophthalmic drugs, which brought about a decline of 4.64% to s.a. Alcon- Couvreur n.v. in 2014. As local enterprises continue to progress, their market share is expected to keep growing in the next few years despite a dominance of imported drug in tobramycin market.
Key Topics Covered:
1 Related Concepts of Tobramycin
2 Market Profile of Tobramycin in China
3 Survey on Sales Status of Tobramycin in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Tobramycin in China, 2010-2014
5 Survey on Dosage Forms of Tobramycin in China, 2010-2014
6 Reference Price of Tobramycin in Chinese Hospitals in 2014
7 Major Manufacturers of Tobramycin in Chinese Market, 2010-2014
8 Market Outlook of Tobramycin in China, 2015-2019
- Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd
- Humanwell Healthcare Group Co., Ltd
- Kangya of Ningxia Pharmaceuticals Co., Ltd
- S.A. Alcon-Couvreur N.V.
- Shanghai Sine Pharmaceutical Laboratories Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/jq34zf/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets